Free Access
| Issue |
J Extra Corpor Technol
Volume 53, Number 1, March 2021
|
|
|---|---|---|
| Page(s) | 46 - 49 | |
| DOI | https://doi.org/10.1051/ject/202153046 | |
| Published online | 15 March 2021 | |
- Khamashta MA, Bertolaccini ML, Ateka-Barrutia O. History. In: Antiphospholipid Syndrome Handbook. London, United Kingdom: Springer; 2010:1–2. [Google Scholar]
- Mackworth-Young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol. 2004;136:393–401. [CrossRef] [PubMed] [Google Scholar]
- Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis. 2006;4:295–306. [CrossRef] [Google Scholar]
- Meroni PL, Raschi E, Camera M, et al. . Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000;15:237–40. [CrossRef] [PubMed] [Google Scholar]
- Meroni PL, Del Papa N, Raschi E, et al. . Beta2-glycoprotein I as a ‘cofactor’ for anti-phospholipid reactivity with endothelial cells. Lupus. 1998;7(Suppl 2):S44–7. [CrossRef] [Google Scholar]
- Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010–21. [CrossRef] [PubMed] [Google Scholar]
- Vaarala O, Alfthan G, Jauhiainen M, et al. . Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923–5. [CrossRef] [PubMed] [Google Scholar]
- Horkko S, Miller E, Dudl E, et al. . Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996;98:815–25. [CrossRef] [PubMed] [Google Scholar]
- Jervis K, Senthilnathan V, Lerner AB. Management of a patient with lupus anticoagulant and antiphospholipid syndrome for off-pump coronary artery bypass grafting using the Hepcon system. Anesth Analg. 2009;108:1116–9. [CrossRef] [PubMed] [Google Scholar]
- Medtronic HMS Plus Hemostasis Management System Version 2.0 Operator’s Manual. 2001. Accessed February 15, 2020. [Google Scholar]
- Duarte-García A, Pham MM, Crowson CS, et al. . The epidemiology of antiphospholipid syndrome: A population-based study. Arthritis Rheumatol. 2019;71:1545–52. [CrossRef] [PubMed] [Google Scholar]
- Lockshin M, Tenedios F, Petri M, et al. . Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23. [CrossRef] [PubMed] [Google Scholar]
- Uden DL, Seay RE, Kriesmer PJ, et al. . The effect of heparin on three whole blood activated clotting tests and thrombin time. ASAIO Trans. 1991;37:88–91. [PubMed] [Google Scholar]
- Sniecinski RM, Bennett-Guerrero E, Shore-Lesserson L. Anticoagulation management and heparin resistance during cardiopulmonary bypass: A survey of society of cardiovascular anesthesiologists members. Anesth Analg. 2019;129:e41–4. [CrossRef] [PubMed] [Google Scholar]
- Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardio Thorac Surg. 2008;33:168–81. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.